Business Overview: KORU Medical Systems, Inc. (NASDAQ: KRMD)

Executive Summary

KORU Medical Systems, Inc. (formerly Repro Med Systems), based in Mahwah, New Jersey, develops, manufactures, and sells large-volume subcutaneous infusion systems — mechanical pumps that deliver 10 mL or more of a drug under the skin without needing batteries or electricity.

Its flagship FREEDOM Infusion System — comprising the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and Precision Flow Rate Tubing — is, by the company's own description, "the market leading delivery system in the U.S." for subcutaneous immunoglobulin (SCIg) therapy used to treat Primary Immunodeficiency Disease (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

1. Core Business Model & How They Work

[ Design Mechanical Infusion Hardware ] ➡️ [ Manufacture FREEDOM System Components ] ➡️ [ Sell via Direct Sales + 9 Distributors ] ➡️ [ End Use: SCIg Infusion for PIDD/CIDP Patients ] ➡️ [ Pharma Services / Clinical Trial Partnerships for New Drugs ]

KORU sells mainly through distribution rather than direct-to-patient: nine distributors (three U.S., six international) generated about 77% of 2025 net revenue, with a single U.S. distributor alone contributing roughly 29%. Beyond its core PIDD/CIDP business, KORU runs a pharma services line — supplying trial product and non-recurring engineering services to drug developers testing new large-volume subcutaneous drugs; the company estimates about 170 large-volume subcutaneous drugs (over 2 mL) are currently in development, each a potential future customer for its delivery hardware.

2. Competitive Landscape

The filing names no specific competitor, instead grouping rivals by delivery technology: electronic (volumetric) pumps, elastomeric (infuser) pumps, and other fully mechanical pumps. For newer drugs specifically, it also cites autoinjectors, needle-free injectors, on-body wearables, pen injectors, and prefilled syringes as substitute delivery formats drugmakers could choose instead of partnering with KORU.

3. Strategic Strengths & Risks

Strengths: a genuinely entrenched position as the stated market leader in mechanical SCIg delivery for PIDD/CIDP, a battery-free design that differentiates it from electronic pump competitors, and an emerging pharma-services pipeline (170 drugs in development) that gives it exposure to future growth well beyond its current two core indications.

Risks:

• Distributor concentration: 77% of 2025 revenue flowed through just nine distributors, with one U.S. distributor alone representing ~29% — losing that single relationship would be a material blow.
• Declining R&D investment: R&D spending fell from $5.3 million (2024) to $4.4 million (2025), a signal worth watching for a company whose long-term growth thesis depends partly on winning new pharma-services partnerships.
• Format substitution risk: as prefilled syringes and on-body wearables mature, drug developers testing new large-volume subcutaneous therapies could bypass FREEDOM-style mechanical pumps entirely.
• Small-cap scale: non-affiliate market value of roughly $119 million (as of mid-2025) limits the company's capital flexibility relative to larger medtech competitors.

4. Summary Conclusion

KORU Medical is a real, profitable-niche medical device company whose moat is a specific, defensible leadership position in battery-free, large-volume subcutaneous infusion for immunodeficiency and neuropathy care, with a credible secondary growth path supplying pharma developers testing the next generation of large-volume subcutaneous drugs. Its biggest vulnerabilities are distributor concentration and the risk that newer delivery formats (wearables, prefilled syringes) erode the mechanical-pump category over time.